TIMP-1 and Responsiveness to Gemcitabine in Advanced Breast Cancer; Results from a Randomized Phase III Trial from the Danish Breast Cancer Cooperative Group

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2014 Jun 3

PMID 24884504

Authors

Charlotte Levin Tykjaer Jorgensen

Christina Bjerre

Bent Ejlertsen

Karsten D Bjerre

Eva Balslev

Annette Bartels

Nils Brunner

Dorte L Nielsen

Affiliations

Soon will be listed here.

Abstract

Background: Tissue inhibitor of metalloproteinases-1 (TIMP-1) has anti-apoptotic functions, which may protect TIMP-1 positive cancer cells from the effects of chemotherapy such as docetaxel and gemcitabine. The purpose of the present study was to evaluate TIMP-1 immunoreactivity as a prognostic and predictive marker in advanced breast cancer patients receiving docetaxel (D) or gemcitabine plus docetaxel (GD).

Methods: Patients with locally advanced or metastatic breast cancer who were assigned to D or GD by participation in a randomized phase III trial were included in the study. Assessment of TIMP-1 status was performed retrospectively on primary tumor whole-tissue sections by immunohistochemistry and tumor samples were considered positive if epithelial breast cancer cells were stained by the anti-TIMP-1 monoclonal antibody VT7. Time to progression (TTP) was the primary endpoint. Overall survival (OS) and response rate (RR) were secondary endpoints. Associations between TIMP-1 status and outcome after chemotherapy were analyzed by Kaplan-Meier estimates and Cox proportional hazards regression models.

Results: TIMP-1 status was available from 264 of 337 patients and 210 (80%) of the tumors were classified as cancer cell TIMP-1 positive. No significant difference for TTP between TIMP-1 positive versus TIMP-1 negative patients was observed in multivariate analysis, and RR did not differ according to TIMP-1 status. However, patients with TIMP-1 positive tumors had a significant reduction in OS events (hazard ratio = 0.71, 95% confidence interval (CI) = 0.52-0.98, P = 0.03). Additionally, a borderline significant interaction for OS was observed between TIMP-1 status and benefit from GD compared to D (Pinteraction = 0.06) such that median OS increased by nine months for TIMP-1 negative patients receiving GD.

Conclusions: TIMP-1 status was an independent prognostic factor for OS but not TTP in patients with advanced breast cancer receiving either D or GD. There was no statistically significant interaction between TIMP-1 status and treatment, but a trend towards an incremental OS from the addition of gemcitabine to docetaxel in patients with TIMP-1 negative tumors suggests further investigation.

References

Del Casar J, Gonzalez L, Alvarez E, Junquera S, Marin L, Gonzalez L . Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of breast carcinomas. Breast Cancer Res Treat. 2009; 116(1):39-52. DOI: 10.1007/s10549-009-0351-z. View

Sorensen I, Fenger C, Winther H, Foged N, Lademann U, Brunner N . Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem. 2006; 54(10):1075-86. PMC: 3957804. DOI: 10.1369/jhc.5A6896.2006. View

Chirco R, Liu X, Jung K, Kim H . Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 2006; 25(1):99-113. DOI: 10.1007/s10555-006-7893-x. View

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S . American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25(33):5287-312. DOI: 10.1200/JCO.2007.14.2364. View

Ng SSW , Tsao M, Chow S, Hedley D . Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 2000; 60(19):5451-5. View

Jiang Y, Goldberg I, Eric Shi Y . Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene. 2002; 21(14):2245-52. DOI: 10.1038/sj.onc.1205291. View

Perez E . Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Breast Cancer Res Treat. 2008; 114(2):195-201. DOI: 10.1007/s10549-008-0005-6. View

Stetler-Stevenson W . Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal. 2008; 1(27):re6. PMC: 2493614. DOI: 10.1126/scisignal.127re6. View

Hertel P, Tu D, Ejlertsen B, Jensen M, Balslev E, Jiang S . TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients. Breast Cancer Res Treat. 2011; 132(1):225-34. DOI: 10.1007/s10549-011-1896-1. View

10.

El Saghir N, Tfayli A, Hatoum H, Nachef Z, Dinh P, Awada A . Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives. Crit Rev Oncol Hematol. 2011; 80(3):433-49. DOI: 10.1016/j.critrevonc.2011.01.010. View

11.

Schrohl A, Look M, Meijer-Van Gelder M, Foekens J, Brunner N . Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study. BMC Cancer. 2009; 9:322. PMC: 2754488. DOI: 10.1186/1471-2407-9-322. View

12.

Nielsen K, Ejlertsen B, Moller S, Jorgensen J, Knoop A, Knudsen H . The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. Acta Oncol. 2008; 47(4):725-34. DOI: 10.1080/02841860801995396. View

13.

Huang P, Chubb S, Hertel L, GRINDEY G, Plunkett W . Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991; 51(22):6110-7. View

14.

Kuvaja P, Hulkkonen S, Pasanen I, Soini Y, Lehtonen S, Talvensaari-Mattila A . Tumor tissue inhibitor of metalloproteinases-1 (TIMP-1) in hormone-independent breast cancer might originate in stromal cells, and improves stratification of prognosis together with nodal status. Exp Cell Res. 2012; 318(10):1094-103. DOI: 10.1016/j.yexcr.2012.03.009. View

15.

Bigelow R, Williams B, Carroll J, Daves L, Cardelli J . TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro. Breast Cancer Res Treat. 2008; 117(1):31-44. DOI: 10.1007/s10549-008-0170-7. View

16.

Lindstrom L, Karlsson E, Wilking U, Johansson U, Hartman J, Lidbrink E . Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012; 30(21):2601-8. DOI: 10.1200/JCO.2011.37.2482. View

17.

Knoop A, Knudsen H, Balslev E, Rasmussen B, Overgaard J, Nielsen K . retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:.... J Clin Oncol. 2005; 23(30):7483-90. DOI: 10.1200/JCO.2005.11.007. View

18.

Henriksen K, Rasmussen B, Lykkesfeldt A, Moller S, Ejlertsen B, Mouridsen H . An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer. Acta Oncol. 2009; 48(4):522-31. DOI: 10.1080/02841860802676383. View

19.

Hertel L, Boder G, Kroin J, Rinzel S, Poore G, TODD G . Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). Cancer Res. 1990; 50(14):4417-22. View

20.

Subramaniam D, Isaacs C . Utilizing prognostic and predictive factors in breast cancer. Curr Treat Options Oncol. 2005; 6(2):147-59. DOI: 10.1007/s11864-005-0022-1. View